Use of transdermal drug formulations in the elderly

Drugs and Aging

Volumn 25, Issue 4, 2008, Pages 269-280

  Kaestli, Laure Zoé ^a   Wasilewski Rasca, Anne Florence ^a   Bonnabry, Pascal ^a   Vogt Ferrier, Nicole ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Elderly; Transdermal

Indexed keywords

APOMORPHINE; BUPRENORPHINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; ESTROGEN DERIVATIVE; FENTANYL; GLYCERYL TRINITRATE; INSULIN; LEVODOPA; LISURIDE; MORPHINE; NICOTINE; OPIATE; ORGANIC NITRATE; OXYBUTYNIN; PHYSOSTIGMINE; PLACEBO; PROGESTERONE; RIVASTIGMINE; ROTIGOTINE; SELEGILINE; TACRINE; TESTOSTERONE;

ADJUVANT THERAPY; AGING; ALZHEIMER DISEASE; ANDROPAUSE RELATED DISORDER; ANGINA PECTORIS; ANTICHOLINERGIC EFFECT; APPLICATION SITE REACTION; CHRONIC PAIN; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEMENTIA; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RELEASE; ELDERLY CARE; HUMAN; HYDRATION; HYPERTENSION; LIVER TOXICITY; LOW DRUG DOSE; MAJOR DEPRESSION; NAUSEA; NOTE; OVERACTIVE BLADDER; PARKINSON DISEASE; PRIORITY JOURNAL; SIDE EFFECT; SKIN FUNCTION; SKIN PENETRATION; SKIN STRUCTURE; SOMNOLENCE; TRANSDERMAL DRUG ADMINISTRATION; TRANSDERMAL PATCH; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

EID: 41149138782     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825040-00001     Document Type: Note

References (85)

1. Moser K, Kriwet K, Naik A, et al. Passive skin penetration enhancement and its quantification in vitro. Eur J Pharm Biopharm 2001; 52: 103-12
2. Aiache JM, Devissaguet JP, Guyot-Hermann AM. Galenica 2: biopharmacie. Paris: Technique et Documentation, 1978
3. Ranade VV. Drug delivery systems 6: transdermal drug delivery. J Clin Pharmacol 1991; 31: 401-18
4. Potts RO, Guy RH. Predicting skin permeability. Pharm Res 1992; 9: 663-9
5. Rikke HL, Nielsen F, Sorensen JA, et al. Dermal penetration of fentanyl: inter- and intraindividual variations. Pharmacol Toxicol 2003; 93: 244-8
6. Brown MB, Martin GP, Jones SA, et al. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv 2006; 13: 175-87
7. Buri P, Puisieux F, Doelker E, et al. Formes pharmaceutiques nouvelles. Paris: Technique et Documentation, 1985
8. Meidan VM, Michniak BB. Emerging technologies in transdermal therapeutics. Am J Ther 2004; 11: 312-6
9. Thomas DR. Age-related changes in wound healing. Drugs Aging 2001; 18: 607-20
10. Aubert JP, Crickx B. La peau du sujet âgé. Rev Pratic 2003; 17: 1209-12
11. Lavker RM. Structural alterations in exposed and unexposed aged skin. J Invest Dermatol 1979; 73: 59-66
12. Roskos KV, Maibach HI. Percutaneous absorption and age: implications for therapy. Drugs Aging 1992; 2: 432-49
13. Gilchrest BA, Blog FB, Szabo G. Effects of aging and chronic sun exposure on melanocytes in human skin. J Invest Dermatol 1979; 73: 141-3
14. Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (I): blood flow, pH, thickness, and ultrasound echogenicity. Skin Res Technol 2005; 11: 221-35
15. Jacobson TM, Yuksel KU, Geesin JC, et al. Effects of aging and xerosis on the amino acid composition of human skin. J Invest Dermatol 1990; 95: 296-300
16. Bernstein EF, Underhill CB, Hahn PJ, et al. Chronic sun exposure alters both the content and distribution of dermal glycosaminoglycans. Br J Dermatol 1996; 135: 255-62
17. Saint Leger D, Francois AM, Leveque JL, et al. Age-associated changes in stratum corneum lipids and their relation to dryness. Dermatologica 1988; 177: 159-64
18. Makrantonaki E, Zouboulis CC. Characteristics and pathomechanisms of endogenously aged skin. Dermatology 2007; 214: 352-60
19. Pochi PE, Strauss JS, Downing DT. Age related changes in sebaceous gland activity. J Invest Dermatol 1979; 73: 108-11
20. Waller JM, Maibach HI. Age and skin structure and function - a quantitative approach (II): protein, glycosaminoglycan, water, and lipid content and structure. Skin Res Technol 2006; 12: 145-54
21. Uitto J. Connective tissue biochemistry of the aging dermis: age-associated alterations in collagen and elastin. Clin Geriatr Med 1989; 5: 127-47
22. Kelly RI, Pearse R, Bull RH, et al. The effects of aging on the cutaneous microvasculature. J Am Acad Dermatol 1995; 33: 749-56
23. Roskos KV, Bircher AJ, Maibach HI, et al. Pharmacodynamic measurements of methyl nicotinate percutaneous absorption: the effect of aging on microcirculation. Br J Dermatol 1990; 122: 165-71
24. Sandby-Moller J, Poulsen T, Wulf HC. Epidermal thickness at different body sites: relationship to age, gender, pigmentation, blood content, skin type and smoking habits. Acta Derm Venereol 2003; 83: 410-3
25. Branchet MC, Boisnic S, Frances C, et al. Skin thickness changes in normal aging skin. Gerontology 1990; 36: 28-35
26. Yamamoto A, Serizawa S, Ito M, et al. Effect of aging on sebaceous gland activity and on the fatty acid composition of wax esters. J Invest Dermatol 1987; 89: 507-12
27. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids. Clin Pharmacokinet 2000; 38: 59-89
28. Roskos KV, Maibach HI, Guy RH. The effect of aging on percutaneous absorption in man. J Pharmacokinet Biopharm 1989; 17: 617-30
29. Berner B, John VA. Pharmacokinetic characterisation of transdermal delivery systems. Clin Pharmacokinet 1994; 26: 121-34
30. Ansel HC, Popovich NG. Pharmaceutical dosage forms and drug delivery systems. Philadelphia (PA): Lea and Febiger, 1990
31. Wasilewski-Rasca AF, Vogt-Ferrier NV. CAPP-INFO -systèmes transdermiques (ou patchs): structure-utilisation-aspects pratiques [online]. Available from URL: http://www.hcuge.ch/Pharmacie/infomedic/cappinfo/cappinfo18. pdf [Accessed 2007 May 7]
32. Beckett AH, Gorrod JW, Taylor DC. Comparison of oral and percutaneous routes in man for the systemic administration of ephedrines. J Pharm Pharmacol 1972; 24: 65-70
33. Burris JF, Papademetriou V, Wallin JD, et al. Therapeutic adherence in the elderly: transdermal clonidine compared to oral verapamil for hypertension. Am J Med 1991; 91: 22S-8S
34. Carmichael AJ. Skin sensitivity and transdermal drug delivery: a review of the problem. Drug Saf 1994; 10: 151-9
35. Murphy M, Carmichael AJ. Transdermal drug delivery systems and skin sensitivity reactions: incidence and management. Am J Clin Dermatol 2000; 1: 361-8
36. Pfeiffer RF. Potential of transdermal drug delivery in Parkinson's disease. Drugs Aging 2002; 19: 561-70
37. Li GL, Vries JJ, van Steeg TJ, et al. Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pre-treatment. J Control Release 2005; 101: 199-208
38. Woitalla D, Muller T, Benz S, et al. Transdermal lisuride delivery in the treatment of Parkinson's disease. J Neural Transm 2004; 68 Suppl.: 89-95
39. MacMahon DG. Use of apomorphine in clinical practice. Adv Neurol 1999; 80: 529-33
40. Guldenpfennig WM, Poole KH, Sommerville KW, et al. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol 2005; 28: 106-10
41. Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of rotigotine in early Parkinson disease. Neurology 2007; 68: 272-6
42. LeWitt PA, Lyons KE, Pahwa R, et al. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 2007; 68: 1262-7
43. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513-20
44. Priano L, Gasco MR, Mauro A, et al. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 2006; 23: 357-75
45. Moller HJ, Hampel H, Hegerl U, et al. Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type. Pharmacopsychiatr 1999; 32: 99-106
46. Levy A, Brandeis R, Treves TA, et al. Transdermal physostigmine in the treatment of Alzheimer's disease. Alzheimer Dis Assoc Disord 1994; 8: 15-21
47. Kankkunen T, Sulkava R, Vuorio M, et al. Transdermal iontophoresis of tacrine in vivo. Pharm Res 2002; 19: 704-7
48. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease: rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456-67
49. Wilson AL, Langley LK, Monley J, et al. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav 1995; 51: 509-11
50. Snaedal J, Johannesson T, Jonsson JE, et al. The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease. Dementia 1996; 7: 47-52
51. Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994; 51: 896-900
52. Baldereschi M, Di Carlo A, Lepore V, et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology 1998; 50: 996-1002
53. Transdermal selegiline. Med Lett Drugs Ther 2006; 1235: 41-2
54. Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 2006; 26: 579-86
55. Robinson DS, Amsterdam JD. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. J Affect Disord 2008; 105: 15-23
56. Pae CU, Lim HK, Han C, et al. Selegiline transdermal system: current awareness and promise. Prog Neuropsychopharmacol Biol Psychiatr 2007; 31: 1153-63
57. Frampton JE, Plosker GL. Selegiline transdermal system in the treatment of major depressive disorder. Drugs 2007; 67: 257-65
58. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61: 2289-307
59. Payne R. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. Semin Oncol 1998; 25: 47-53
60. Payne R, Mathias SD, Pasta DJ, et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998; 16: 1588-93
61. Kornick CA, Santiago-Palma J, Moryl N, et al. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 2003; 26: 951-73
62. Klockgether-Radke AP, Gaus P, Neumann P. Opioid intoxication following transdermal administration of fentanyl. Anaesthesist 2002; 51: 269-71
63. Klockgether-Radke A, Hildebrandt J. Opioid intoxication: inappropriate administration of transdermal fentanyl. Anaesthesist 1997; 46: 428-9
64. Compendium Suisse des médicaments. Basel: Documed, 2007 [online]. Available from URL: http://www.kompendium.ch [Accessed 2007 May 9]
65. Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med 2006; 20: 25-30
66. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004; 26: 1808-20
67. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 2003; 63: 1999-2012
68. Girdler SS, Hinderliter AL, Wells EC, et al. Transdermal versus oral estrogen therapy in postmenopausal smokers: hemodynamic and endothelial effects. Obstet Gynecol 2004; 103: 169-80
69. Dören M, Samsioe G. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1995. Hum Reprod Update 2000; 6: 419-26
70. Sitruk-Ware R. Routes of delivery for progesterone and progestins. Maturitas 2007; 57: 77-80
71. Lund BC, Bever-Stille KA, Perry PJ. Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men. Pharmacotherapy 1999; 19: 951-6
72. Beer TM, Bland LB, Bussiere JR, et al. Testosterone loss and estradiol administration modify memory in men. J Urol 2006; 175: 130-5
73. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabetes Metab 2003; 20: 886-98
74. King MJ, Badea I, Solomon J, et al. Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther 2002; 4: 479-88
75. Lee S, Snyder B, Newnham RE, et al. Noninvasive ultrasonic transdermal insulin delivery in rabbits using the light-weight cymbal array. Diabetes Technol Ther 2004; 6: 808-15
76. Longobardi G, Ferrara N, Abete P, et al. Efficacy of transdermal nitroglycerin patches evaluated by dipyridamole-induced myocardial ischemia in patients with coronary artery disease: comparison between continuous and intermittent schedule. Cardiovasc Drugs Ther 2002; 16: 535-42
77. Kiraly C, Kiss A, Timar S, et al. Effects of long-term transdermal nitrate treatment on left ventricular function in patients following myocardial infarction. Clin Cardiol 2003; 26: 120-6
78. Klemsdal TO, Gjesdal K. Intermittent or continuous transdermal nitroglycerin: still an issue, or is the case closed? Cardiovasc Drugs Ther 1996; 10: 5-10
79. Parker JO, Amies MH, Hawkinson RW, et al. Intermittent transdermal nitroglycerin therapy in angina pectoris: clinically effective without tolerance or rebound. Minitran Efficacy Study Group. Circulation 1995; 91: 1368-74
80. Bang LM, Easthope SE, Perry CM. Transdermal oxybutynin for overactive bladder. Drugs Aging 2003; 20: 857-64
81. Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005; 23: 263-70
82. Dmochowski RR, Starkman JS, Davila GW. Transdermal drug delivery treatment for overactive bladder. Int Braz J Urol 2006; 32: 513-20
83. Wasilewski-Rasca AF, Bonnabry P. Systèmes thérapeutiques transdermiques: aspects pratiques chez le patient âgé. Med Hyg 2004; 62: 2320-5
84. Lee AH, Anderson PO. Giving partial doses of transdermal patches. Am J Health Syst Pharm 1997; 54: 1759-60
85. Dispositifs transdermiques contenant de l'aluminium: risques de progesbrûlures [editorial]. Rev Prescrire 2007; 27: 191-2